Patrick Sipila

Patrick Sipila

Auto-generated profile, based on publicly available information

Patrick Sipila

Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Canada; Section of Pediatric Hematology, Oncology, Transplant and Immunology, Alberta Children's Hospital, Calgary, Alberta, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2024 in Blood Neoplasia
Verified
Journal Article
Open access
STSon Tran
Son Tran
PSPatrick Sipila
Patrick Sipila
MFMelanie M. Frigault
Melanie M. Frigault
BSBeatrix Stelte-Ludwig
Beatrix Stelte-Ludwig
AJAmy J. Johnson
Amy J. Johnson
ANAru Narendran
Aru Narendran
• Targeting cyclin-dependent kinase 9 with enitociclib induces apoptotic cell death in MM and demonstrates synergy in drug combinations. • Enitociclib may be an effective treatment for MM as a single agent or in combination therapies in future clinical studies.

29 January 2026 in Human Immunology
Verified
Journal Article
Open access
SLSamuel Lokanc
Samuel Lokanc
PSPatrick Sipila
Patrick Sipila
GCGeoffrey D.E. Cuvelier
Geoffrey D.E. Cuvelier
LMLuis Murguía-Favela
Luis Murguía-Favela
NWNicola Am Wright
Nicola Am Wright
ANAru Narendran
Aru Narendran
Inborn Errors of Immunity (IEI) are genetic disorders impairing the immune system, increasing susceptibility to infections, autoimmunity, inflammation, and malignancies. Mutations in over 500 genes have been shown to cause IEI. This study investigated IEI-related differential gene expression by examining the somatic transcriptomes of cancers. RNA-sequencing data from cancers were obtained from TCGA and TARGET databases, alongside healthy tissue data from GTEx, and the differentially expressed gene set was filtered for 592 IEI-related genes. To examine the differential expression of genes across cancers, odds ratios were computed for enrichment of IEI-related genes. Pathway analysis on the differentially expressed IEI-related genes identified immune pathways that are significantly represented. IEI-genes that were significantly dysregulated include TMPRSS15, SEMA3E, ANGPT1, CFH, F5, CFB, CFD, CFH, and CR2. Interestingly, complement-related pathways were the most altered in our analysis. Furthermore, IEI-related genes are more likely to be differentially expressed compared to non-IEI genes in certain cancers. This study presents bioinformatic analyses of pan-cancer genomic datasets, identifying distinct IEI-associated gene expression changes. The findings provide insights into the role of immunological pathways, specifically the complement system, in cancer. Further investigation into the identified gene alterations could advance the care of a vulnerable group of cancer patients.